



## Incyte Announces Pricing of Public Offering of 4,945,000 Shares of Common Stock

September 8, 2017

WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 8, 2017-- Incyte Corporation (Nasdaq: INCY) (the "Company") today announced the pricing of its underwritten public offering of 4,945,000 shares of its common stock. The Company has granted the underwriter an option to purchase up to an additional 741,750 shares of common stock. The offering is expected to close on September 12, 2017, subject to customary closing conditions.

The Company intends to use the net proceeds of this offering for general corporate purposes, including working capital, research and development activities, capital expenditures and potential strategic transactions.

The underwriter intends to offer the shares from time to time for sale in one or more transactions on The NASDAQ Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.

BofA Merrill Lynch is acting as the sole underwriter of this offering.

The shares are being issued pursuant to an effective shelf registration statement. Before you invest, you should read the prospectus included in that registration statement and the documents incorporated by reference in that registration statement as well as the prospectus supplement related to the offering. You may obtain these documents free of charge by visiting EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov). A copy of the prospectus supplement and related prospectus relating to the offering may be obtained, when available, from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department or by email at [dq.prospectus\\_requests@baml.com](mailto:dq.prospectus_requests@baml.com).

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy the Company's common stock, nor shall there be any sale of the common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state. This offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective shelf registration statement.

### About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.

### Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements with respect to the anticipated closing date of the offering and the intended use of net proceeds from the offering, are all forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including those related to the satisfaction of the conditions to closing of the offering, risks relating to our dependence upon our revenues from JAKAFI, cash requirements arising from the development of new products by us and our current and potential collaborators, the risk of significant delays or costs in obtaining regulatory approvals, risks relating to our collaborators' ability to develop and commercialize drug candidates, and cash requirements arising from our business development activities, the fact that Incyte management will have broad discretion in the use of the proceeds from any sale of the shares, and other risks detailed from time to time in Incyte's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Incyte disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170908005432/en/>

Source: Incyte Corporation

Incyte Corporation  
David W. Gyska, +1-302-498-6700  
[dgyaska@incyte.com](mailto:dgyaska@incyte.com)